Chicago Capital LLC Sells 427,473 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Chicago Capital LLC reduced its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 47.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 476,937 shares of the medical device company's stock after selling 427,473 shares during the period. Chicago Capital LLC owned approximately 0.73% of Tandem Diabetes Care worth $14,108,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. RiverPark Advisors LLC bought a new stake in shares of Tandem Diabetes Care in the 4th quarter valued at approximately $27,000. State of Wyoming grew its stake in Tandem Diabetes Care by 45.8% during the 4th quarter. State of Wyoming now owns 821 shares of the medical device company's stock worth $37,000 after buying an additional 258 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in Tandem Diabetes Care by 51.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the medical device company's stock worth $67,000 after buying an additional 1,099 shares during the last quarter. Stephens Inc. AR grew its stake in Tandem Diabetes Care by 17.6% during the 1st quarter. Stephens Inc. AR now owns 2,120 shares of the medical device company's stock worth $86,000 after buying an additional 317 shares during the last quarter. Finally, Jefferies Financial Group Inc. bought a new position in Tandem Diabetes Care during the 4th quarter worth $89,000.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Citigroup upped their price objective on Tandem Diabetes Care from $25.00 to $31.00 and gave the stock a "neutral" rating in a research note on Friday, March 15th. Stifel Nicolaus upgraded Tandem Diabetes Care from a "hold" rating to a "buy" rating and upped their price objective for the stock from $24.00 to $37.00 in a research note on Tuesday, March 26th. Finally, StockNews.com upgraded Tandem Diabetes Care from a "sell" rating to a "hold" rating in a research note on Thursday, March 21st. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $36.36.

Tandem Diabetes Care Price Performance

Shares of Tandem Diabetes Care stock traded down $0.35 during trading on Tuesday, hitting $33.50. The stock had a trading volume of 1,783,122 shares, compared to its average volume of 1,874,286. The company has a debt-to-equity ratio of 0.91, a current ratio of 3.83 and a quick ratio of 3.02. The firm has a market cap of $2.20 billion, a P/E ratio of -9.74 and a beta of 1.11. The business has a fifty day moving average of $27.37 and a two-hundred day moving average of $23.83. Tandem Diabetes Care, Inc. has a fifty-two week low of $13.82 and a fifty-two week high of $43.51.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Tandem Diabetes Care had a negative net margin of 29.77% and a negative return on equity of 31.48%. The firm had revenue of $196.80 million during the quarter, compared to analyst estimates of $204.86 million. On average, sell-side analysts expect that Tandem Diabetes Care, Inc. will post -1.62 earnings per share for the current fiscal year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.